ETIDIOH - NEW

  {Summary} Situation at a glance On 1 December 2025, the Ministry of Health (MoH) of the Democratic Republic of the Congo (DRC) declared the end of the Ebola virus disease (EVD) outbreak which had been declared on 4 September 2025.  The end was declared after two consecutive incubation periods (a total of 42 days) since the last person confirmed with EVD tested negative for the virus and was discharged on 19 October 2025.  A total of 64 cases (53 confirmed, 11 probable), including 45 deaths (CFR 70.3%), were reported from six health areas in Bulape Health Zone, Kasai Province .  WHO and partners provided technical, operational and financial support to the government to contain the outbreak.  This is the country’s 16th outbreak of Ebola.  Although the outbreak has been declared over , health authorities are maintaining surveillance to rapidly identify and respond to any re-emergence.  Risk communication and community engagement activities will continue...

  Description of the Event Date when the trigger was met :  12-11-2025 What happened, where and when? -- On 14 November 2025 , the Federal Ministry of Health (FMOH), in collaboration with the Ethiopian Public Health Institute (EPHI), issued a press release declaring an outbreak of Marburg virus disease in the South Region of Ethiopia .  -- As of 26 November 2025, 78 laboratory tests have been conducted, of which twelve confirmed cases , including seven confirmed deaths , have been reported, three cases remain probable .  -- Of the twelve confirmed cases, five are currently alive , three on treatment , and two discharged .  -- More than 300 contacts have been identified and are under active follow-up.  -- Given the high fatality potential and rapid transmissibility of Marburg, (MVD) an immediate and coordinated public health response is essential.  - Early detection, isolation, contact tracing , and community sensitization are critical to prevent furthe...

  The Ministry of Health and the Ethiopian Public Health Institute (EPHI) have released a press statement containing updated information regarding the Marburg virus disease . They stated that laboratory tests have confirmed the occurrence of Marburg virus disease in the Southern Ethiopia Region .  Up to now, 73 suspected individuals have been tested; among them, 6 patients have died due to the virus, as confirmed by the EPHI reference laboratory. Five additional patients are currently receiving treatment. It was also noted that 349 people who had contact with the confirmed cases are under follow-up, and 119 of them have already completed their isolation period . Dr. Mekdes Daba , Minister of Health, expressed condolences for those who lost their lives due to the virus and extended sympathy to their families, relatives, and friends. She further explained that isolation centers have been established in affected areas, trained personnel are deployed, and essential medical supplie...

  Abstract The wildlife reservoir and spillover mechanisms of Ebola virus remain elusive despite extensive research efforts in endemic areas. This study employed a One Health approach to examine the virus’ circulation in wildlife and the associated human exposure risks in the Tshuapa province of the Democratic Republic of the Congo . We screened 1049 samples from 919 animals , predominantly small mammals , collected in 2021, and 380 samples from inhabitants of Inkanamongo village, the site of an Ebola virus disease outbreak in 2014. These samples were screened for evidence of current (RNA) or past (IgG antibodies) Ebola virus infections. We also conducted interviews with 167 individuals in the surrounding districts to assess their interactions with wildlife . While no Ebola virus RNA was detected in the wildlife samples , anti-orthoebolavirus IgG antibodies were found in 13 bats and 38 rodents . Among the human participants , 120 individuals had IgG antibodies against at least 1 or...

  {Excerpts} Situation at a glance On 12 November 2025, WHO noted a press release from the Ethiopian Ministry of Health (MoH), and the Ethiopian Public Health Institute (EPHI), announcing suspected viral hemorrhagic viral fever (VHF) in Jinka town, South Ethiopia Regional State, Ethiopia.  On 14 November 2025 , the Ministry of Health of Ethiopia confirmed that the cases previously reported as suspected VHF were Marburg virus disease (MVD).  Molecular testing conducted by the National Reference Laboratory at EPHI identified Marburg virus (MARV) in patient samples.  As of 20 November 2025, 33 laboratory tests have been conducted, of which six confirmed cases , including three deaths , have been reported.  Of the six confirmed cases, three are currently alive and on treatment.  In addition to the lab-confirmed cases , a further three epidemiologically linked cases could not be tested; all three are deceased and recorded as probable cases.  A total of 206 ...

  14 November 2025 Addis Ababa—Ethiopia’s Ministry of Health has confirmed an outbreak of Marburg virus disease in the South Ethiopia Region, the first of its kind in the country , following laboratory testing of samples from a cluster of suspected cases of viral haemorrhagic fever. Genetic analysis by the Ethiopia Public Health Institute revealed that the virus is of the same strain as the one that has been reported in previous outbreaks in other countries in East Africa .  A total of nine cases have been reported in the outbreak that has affected Jinka town in the South Ethiopia Region. The national authorities are scaling up response including community-wide screening, isolation of cases, treatment, contact tracing and public awareness campaigns to curb the spread of the Marburg virus, which is in the same family of viruses that cause Ebola virus disease. The World Health Organization (WHO) and partners are supporting the government as it intensifies response to halt the sp...

  13 November 2025, Addis Ababa – The Africa Centres for Disease Control and Prevention (Africa CDC) is closely monitoring reports of a suspected viral haemorrhagic fever (VHF) in Jinka, Southern Region, Ethiopia . On 12 November 2025 , the Ethiopia Public Health Institute (EPHI) notified Africa CDC of eight suspected cases, with clinical samples collected and submitted to the National Reference Laboratory for further testing. As investigations continue, no confirmed aetiology has yet been established. From London where he was on official mission, the Director General of Africa CDC, H.E. Dr. Jean Kaseya had a call the same day with the Ethiopian Minister of Health H.E. Dr. Mekdes Daba to congratulate her for early detection and the transparency that characterized Ethiopia when there is a public health event, and to extend the support from Africa CDC and the entire continent to quickly contain that. During the Africa CDC Weekly Press Briefing on Health Emergencies held on 13 Novembe...

  Abstract Background :  Lassa fever (LF) is an acute viral hemorrhagic illness endemic to West Africa, with no licensed vaccines or targeted treatments available, highlighting a critical gap in global health preparedness. T cell-mediated immunity plays a central role in viral control and survival. Synthetic DNA vaccines offer a promising strategy to induce both humoral and cellular immunity against LF. Methods :  A Phase 1b, randomized, double-blind, placebo-controlled trial was conducted to assess the safety, tolerability, and immunogenicity of INO-4500 , a DNA vaccine encoding the Lassa virus (Josiah strain) glycoprotein precursor (GPC). A total of 220 healthy adults were randomized to receive either 1 mg or 2 mg of INO-4500 (intervention), or placebo, administered intradermally (ID) followed by electroporation (EP) at Day 0 and Week 4. Safety was evaluated through Week 48. Primary immunogenicity endpoints included humoral and cellular immune responses at multiple time...

  {Excerpt} Risk statement This risk assessment is based on the current epidemiological and epizootic situation of Rift Valley fever (RVF) in Senegal and Mauritania , from 20 September through 8 October 2025. The risk assessment was conducted separately for each country . However, the findings indicate that the level of risk is the same for both countries across all levels, for both human and animal health .   During this period , Senegal reported 119 confirmed human RVF cases , including 16 deaths , resulting in a case fatality rate (CFR) of 13.4% . Cases were recorded across eight health districts in three regions of Senegal, with the majority in Saint-Louis Region with 110 cases (92%) followed by Louga (four cases) and Matam (one case).  The affected districts in Saint-Louis Region : Podor, Richard-Toll, Dagana, and Saint-Louis are located along the northern border with Mauritania along the Senegal River.   The most affected age groups were 15- 35 years ...

Abstract Sudan virus (SUDV) causes highly lethal outbreaks of hemorrhagic disease throughout Africa , but there has yet to be an approved vaccine or therapeutic to combat this public health threat. The most common route of natural exposure to filoviruses is through mucosal contact which greatly impacts initial viral replication. Historically, SUDV animal models used an intramuscular infection route . Here, we sought to further characterize an animal model using mucosal challenge routes and compared the impact that intramuscular, intranasal, or aerosol exposure had on SUDV pathogenicity in a ferret model . We determined that the route of infection did not significantly impact overall SUDV pathogenicity; only subtle changes were detected in magnitude of viremia and oral viral shedding. Additionally, we sought to determine if preexisting Lloviu virus (LLOV) immunity could protect ferrets from lethal SUDV infection. We found that the previous immunity elicited by LLOV infection was not suf...

Abstract Background .  Sudan virus (SUDV) has caused multiple outbreaks in Uganda over the past two decades, leading to significant morbidity and mortality . The recent outbreaks in 2022 and 2025 highlight the ongoing threat posed by SUDV and the challenges in its containment. This study aims to characterize the epidemiological patterns and phylogenomic evolution of SUDV outbreaks in Uganda, identifying key factors influencing transmission and disease severity.  Methods .  We conducted a retrospective observational study analyzing epidemiological and genomic data from SUDV outbreaks in Uganda between 2000 and 2025. Epidemiological data were collected from official sources, including the Ugandan Ministry of Health and the World Health Organization, supplemented with reports from public health organizations. Genomic sequences of SUDV were analyzed to investigate viral evolution and identify genetic variations associated with pathogenicity and transmissibility.  Results...

Abstract The Sudan virus (SUDV) outbreaks in Uganda in 2022 and 2025 created public health concerns in-country and the entire East African region. There are currently no licensed countermeasures against SUDV . We developed a SUDV vaccine candidate based on a nanocarrier (LIONTM) complexed with an alphavirus-based replicon RNA . Here, we compare the protective efficacy of the LION-SUDV vaccine either encoding the SUDV glycoprotein (GP) alone or in combination with the Ebola virus (EBOV) GP (LION-Combination). A LION-EBOV vaccine which is protective against EBOV was also included to determine the potential for cross-protection against SUDV infection . Single-dose vaccinations were conducted three weeks before challenge with a lethal dose of guinea pig-adapted SUDV using a female guinea pig disease model. We demonstrate 100% survival and protection with the LION-SUDV and the LION-Combination vaccines, while the LION-EBOV vaccine achieved 50% protection. Antigen-specific humoral responses ...

{Summary} Situation at a glance On 26 April 2025, the Ministry of Health (MoH) of Uganda declared the end of the Sudan virus disease (SVD) outbreak after two consecutive incubation periods (a total of 42 days) since the last person confirmed with SVD tested negative for the virus on 14 March 2025.  A total of 14 SVD cases (including 12 confirmed cases and two probable cases) including four deaths (two confirmed and two probable) have been reported during this outbreak.  WHO and partners provided technical , operational and financial support to the government to contain the outbreak.  Although the outbreak has been declared over , health authorities are maintaining surveillance to rapidly identify and respond to any re-emergence.  Risk communication and community engagement will also continue to ensure the community stay informed and stigma to those who were affected is minimized. (...) Source: World Health Organization,  https://www.who.int/emergencies/disease-o...

Abstract In 2018, a clinical trial of four investigational therapies for Ebola virus disease (EVD), known as the PALM trial , was conducted in the Democratic Republic of Congo . All patients received either the antiviral remdesivir (RDV) or a monoclonal antibody product : ZMapp, mAb114 (Ebanga), or REGN-EB3 (Inmazeb). The study concluded that both mAb114 and REGN-EB3 were superior to ZMapp and RDV in reducing mortality from EVD. However, the data suggested that some patients in the RDV and ZMapp groups might have been sicker at the time of treatment initiation. Here, we assessed the efficacy of each of these therapies in a uniformly lethal rhesus monkey model of EVD when treatment was initiated 5 days after Ebola exposure. Treatment with RDV, mAb114, REGN-EB3, and ZMapp each resulted in similar survival (approximately 40% ). Survival was associated with circulating viral load at treatment initiation. A trend of more escape mutants in the GP1 and GP2 domains was observed for the mAb114 ...

{Excerpt} Highlights •  A new strain of Lassa virus (LASV) was successfully isolated and characterized. •  The combination of ribavirin and LHF-535 has been demonstrated to exhibit synergistic effects in inhibiting LASV. •  The findings provide new directions for the development of antiviral drugs and vaccines for Lassa fever. Dear Editor, Lassa virus (LASV) is the causative agent of the acute viral hemorrhagic Lassa fever (LF), which is classified into Mammarenavirus within the Arenaviridae family , with a single-stranded, negative-sense, bi-segmented RNA genome. Due to its high pathogenicity and lethality , LASV is considered as a priority threat to public health , with an estimated cases of 300,000 infections and 5,000 deaths annually . LASV was first isolated and described as a clinical entity in 1969 in Lassa, Nigeria (Garry, 2023). LASV isolates of different geographic and host origins are highly diverse in genomic sequences and phylogenetically classified into up t...

Abstract We report 1.3% (19/1,511) of Egyptian rousette bats (ERBs) in Uganda and Sierra Leone were co-infected with different combinations of Marburg, Sosuga, Kasokero, or Yogue viruses . To prevent infection by those viruses, we recommend avoiding ERB-populated areas, avoiding ERBs and ERB-contaminated objects, and thoroughly washing harvested fruits before consumption. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/5/24-1669_article ____

Abstract In February 2023, the government of Equatorial Guinea declared an outbreak of Marburg virus disease . We describe the response structure and epidemiologic characteristics , including case-patient demographics, clinical manifestations, risk factors , and the serial interval and timing of symptom onset, treatment seeking, and recovery or death . We identified 16 laboratory-confirmed and 23 probable cases of Marburg virus disease in 5 districts and noted several unlinked chains of transmission and a case-fatality ratio of 90% (35/39 cases). Transmission was concentrated in family clusters and healthcare settings . The median serial interval was 18.5 days ; most transmission occurred during late-stage disease . Rapid isolation of symptomatic case-patients is critical in preventing transmission and improving patient outcomes; community engagement and surveillance strengthening should be prioritized in emerging outbreaks. Further analysis of this outbreak and a One Health surveillan...

Abstract Ebola virus (EBOV) and Marburg virus (MARV) are zoonotic filoviruses that cause hemorrhagic fever in humans . Correlative data implicate bats as natural EBOV hosts , but neither a full-length genome nor an EBOV isolate has been found in any bats sampled. Here, we model filovirus infection in the Jamaican fruit bat (JFB), Artibeus jamaicensis, by inoculation with either EBOV or MARV through a combination of oral, intranasal, and subcutaneous routes . Infection with EBOV results in systemic virus replication and oral shedding of infectious virus. MARV replication is transient and does not shed. In vitro, JFB cells replicate EBOV more efficiently than MARV, and MARV infection induces innate antiviral responses that EBOV efficiently suppresses. Experiments using VSV pseudoparticles or replicating VSV expressing the EBOV or MARV glycoprotein demonstrate an advantage for EBOV entry and replication early , respectively, in JFB cells. Overall, this study describes filovirus species-sp...

Situation at a glance On 13 March 2025, the Ministry of Health of the United Republic of Tanzania declared the end of the Marburg virus disease (MVD) outbreak.  This declaration came after two consecutive incubation periods (a total of 42 days) since the last person confirmed with MVD died on 28 January 2025 and was given a safe and dignified burial, in accordance with WHO recommendations.  No new confirmed cases were reported since then.  The outbreak was declared on 20 January 2025 . As of 12 March 2025, two confirmed and eight probable cases were reported by the Ministry of Health from Biharamulo district in Kagera region. All 10 cases died (case fatality ratio 100%), including eight who died before the confirmation of the outbreak. A total of 272 contacts that were listed for monitoring completed their 21-day follow-up as of 10 February 2025. WHO, through its country office, and partners provided technical, operational and financial support to the government to contai...

The UK Health Security Agency has been informed under the International Health Regulations that an individual travelled to England from Nigeria while they were unwell with Lassa fever at the end of February. The individual returned to Nigeria where they were diagnosed . We are now working to identify people who were in contact with the affected individual while they were in the country. Lassa fever does not spread easily between people and the overall risk to the public is very low . If you have not been contacted by UKHSA then you are very unlikely to have had any exposure to Lassa fever and do not need to take action. Lassa fever causes acute infections which can range from very mild symptoms through to a severe viral haemorrhagic fever. People usually become infected with Lassa virus through exposure to food or household items contaminated with urine or faeces of infected rats – present in some West African countries where the disease is endemic. The virus can also be spread between...